AIM
The aim of the present analysis was to develop a core population pharmacokinetic model for the pharmacokinetic properties of immediate-release (IR) exenatide, which can be used in subsequent analyses of novel sustained-release formulations.
METHODS
Data from eight clinical trials, evaluating a wide range of doses and different administration routes, were available for analysis. All modell...
